pp-138 Solution for injection
Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Advanced/metastatic cutaneous melanoma (intratumoral injection in combination with pembrolizumab)
Clinical stage: Phase 3
Modality: Small molecule
Mechanism / Target: STING (Stimulator of Interferon Genes) agonist — activates innate immune pathway, induces type I interferon production, promotes anti-tumour T-cell priming and immune infiltration
Route / form: Intratumoral injection
Differentiation: Direct intratumoral delivery maximises local STING activation while limiting systemic toxicity; abscopal effect potential; complements PD-1 blockade
Manufacturer #39170
Clinical-stage immuno-oncology company advancing STING agonist and bispecific checkpoint therapies. Combines proprietary imaging technology with drug development to characterise immune activity. Wholly owned global rights to late-stage oncology candidates.
None